Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies

Author(s): Santenna Chenchula*, Shoban Babu Varthya and R. Padmavathi

Volume 18, Issue 4, 2022

Published on: 11 January, 2022

Article ID: e100921196392 Pages: 11

DOI: 10.2174/1573399817666210910165402

Price: $65

Abstract

Background: Treatment of diabetes mellitus includes more than one drug of different groups, which may lead to a high pill burden and non-adherence to drugs. We have aimed to systematically analyze the clinical efficacy, safety, and pharmacoeconomic cost-effectiveness of the fixed-dose combination of empagliflozin plus a linagliptin in Type-2 Diabetes mellitus (T2DM) patients.

Methods: A literature search of PubMed/MEDLINE, SCOPUS, Google Scholar, and EMBASE was performed using the MeSH terms and/or keywords“((Single-pill combination) OR ((Fixeddose combination) OR (Combination therapy)) AND (Empagliflozin add on-to Linagliptin) OR (Empagliflozin combined with Linagliptin) OR ((Combination of Empagliflozin and Linagliptin)” from the inception to February 2021.

Results: Search results were found in a total of 13 clinical studies. After removing duplicates and studies not according to inclusion criteria, a total of eight clinical studies (Randomized controlled trials: 7; Observational cohort studies: 1) were included (n=7491). A significant reduction in the primary endpoint, the mean changes in baseline HbA1c at the end of 24 weeks and/or 52 weeks was found in the empagliflozin plus a linagliptin combination group in all included studies. In addition, significant efficacy was seen in decreasing the secondary endpoints such as the mean change in the fasting plasma glucose, systolic and diastolic blood pressure (DBP), and body weight with fewer adverse events than the adverse effects with either drug alone.

Conclusion: After reviewing findings from the available clinical studies of the combination of empagliflozin plus linagliptin, we conclude that the combination is effective, safe, tolerable, and rationale cost effective compared to placebo and either drug alone for the management of T2DM in patients with inadequate glycemic control with metformin alone, patients with intolerance to metformin, increased baseline HbA1c, patients with overweight or obesity and diabetic hypertensive, CHF, atherosclerotic cardiovascular disease, and renal dysfunction patients. Future randomized controlled trials in a larger number of T2DM patients with or without CHF and renal failure patients are recommended.

Keywords: Empagliflozin plus linagliptin, SGLT 2 Inhibitors, DPP-4 Inhibitors, Type2 diabetes mellitus, glycated hemoglobin, rationality, cardiac, renal safety.

[1]
Introduction: Standards of medical care in diabetes-2020. Diabetes Care 2020; 43(1): S1-2.
[http://dx.doi.org/10.2337/dc20-Sint] [PMID: 31862741]
[2]
Payne RA, Avery AJ. Polypharmacy: one of the greatest prescribing challenges in general practice. Br J Gen Pract 2011; 61(583): 83-4.
[http://dx.doi.org/10.3399/bjgp11X556146] [PMID: 21276330]
[3]
Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM 2000; 93(6): 369-74.
[http://dx.doi.org/10.1093/qjmed/93.6.369] [PMID: 10873187]
[4]
Aronson R. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. Curr Med Res Opin 2015; 31(5): 901-11.
[http://dx.doi.org/10.1185/03007995.2015.1027185] [PMID: 25775379]
[5]
SYED WAJID, MENAKA M, FAZIL AHMED, SANA SAMREEN. A literature review on oral hypoglycemic drugs mechanistic aspects. Asian J Pharm Clin Res 2019; 5-10.
[http://dx.doi.org/10.22159/ajpcr.2019.v12i11.35469]
[6]
Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: A systematic review and network meta-analysis. Ann Intern Med 2020; 173(4): 278-86.
[http://dx.doi.org/10.7326/M20-0864] [PMID: 32598218]
[7]
Raedler LA. Glyxambi (empagliflozin/linagliptin): a dual-acting oral medication approved for the treatment of patients with type 2 diabetes. Am health drug benefits 2015; 8: 171-5.
[8]
European medical agency. Glyxambi. 2016. Availalble from: https://www.ema.europa.eu/en/medicines/human/EPAR/glyxambi
[9]
US food and drug administration. FDA approves new treatment for type 2 diabetes. Press release. 2011. Availalble from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253501.htm [Accessed December 25, 2020]
[10]
Glund S, Mattheus M, Runge F, Rose P, Friedrich C. Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed- dose combination tablet. Int J Clin Pharmacol Ther 2017; 55(4): 355-67.
[http://dx.doi.org/10.5414/CP202929] [PMID: 28290274]
[11]
Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs. placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The carmelina randomized clinical trial. JAMA 2019; 321(1): 69-79.
[http://dx.doi.org/10.1001/jama.2018.18269] [PMID: 30418475]
[12]
Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs. glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The carolina randomized clinical trial. JAMA 2019; 322(12): 1155-66.
[http://dx.doi.org/10.1001/jama.2019.13772] [PMID: 31536101]
[13]
McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013; 36(2): 237-44.
[http://dx.doi.org/10.2337/dc12-0706] [PMID: 23033241]
[14]
Groop PH, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab 2017; 19(11): 1610-9.
[http://dx.doi.org/10.1111/dom.13041] [PMID: 28636754]
[15]
Han SY, Yoon SA, Han BG, et al. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study. Diabetes Obes Metab 2018; 20(2): 292-300.
[http://dx.doi.org/10.1111/dom.13059] [PMID: 28719008]
[16]
US food and drug administration. FDA approves Jardiance to treat type 2 diabetes. Press release. 2014. Availalble from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407637.htm [Accessed December 25, 2020]
[17]
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373(22): 2117-28.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]
[18]
Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J Heart Fail 2019; 21(10): 1270-8.
[http://dx.doi.org/10.1002/ejhf.1536] [PMID: 31584231]
[19]
Inzucchi SE, Davies MJ, Khunti K, Trivedi P, George JT, Zwiener I. Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab 2021; 23(2): 425-33.
[PMID: 33084149]
[20]
Kovil R, Saboo B, Shah K, et al. Single-pill combination of empagliflozin and linagliptin in real world indian type 2 diabetes patient (GRID). J Assoc Physicians India 2020; 68(10): 53-5.
[PMID: 32978926]
[21]
Kaku K, Haneda M, Tanaka Y, et al. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two- part, randomized, placebo-controlled trial. Diabetes Obes Metab 2019; 21(1): 136-45.
[http://dx.doi.org/10.1111/dom.13496] [PMID: 30091172]
[22]
Kawamori R, Haneda M, Suzaki K, et al. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2018; 20(9): 2200-9.
[http://dx.doi.org/10.1111/dom.13352] [PMID: 29766636]
[23]
Tinahones FJ, Gallwitz B, Nordaby M, et al. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel- group trials. Diabetes Obes Metab 2017; 19(2): 266-74.
[http://dx.doi.org/10.1111/dom.12814] [PMID: 27762093]
[24]
Søfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: A 24-week randomized, double-blind, parallel- group trial. Diabetes Care 2017; 40(2): 201-9.
[http://dx.doi.org/10.2337/dc16-1347] [PMID: 27913576]
[25]
Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes care 2015; 38(3): 394-402. Erratum in: Diabetes Care. 2015;38:1173
[http://dx.doi.org/10.2337/dc14-2365] [PMID: 25633662]
[26]
DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015; 38(3): 384-93.
[http://dx.doi.org/10.2337/dc14-2364] [PMID: 25583754]
[27]
Jung S, Bosch A, Kannenkeril D, et al. Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes. Eur Heart J Cardiovasc Pharmacother 2020; 6(6): 364-71.
[http://dx.doi.org/10.1093/ehjcvp/pvz078] [PMID: 31816038]
[28]
Gallwitz B. A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes. Expert Opin Drug Saf 2017; 16(12): 1399-405.
[http://dx.doi.org/10.1080/14740338.2017.1382471] [PMID: 28934557]
[29]
Watada H, Yamauchi T, Yamamoto F, et al. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials. Expert Opin Drug Saf 2020; 19(9): 1193-202.
[http://dx.doi.org/10.1080/14740338.2020.1782884] [PMID: 32552153]
[30]
FDA revises labels of SGLT2 inhibitors for diabetes to include warning. US food and drug administration 2020.
[31]
Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38(9): 1687-93.
[http://dx.doi.org/10.2337/dc15-0843] [PMID: 26078479]
[32]
Lingvay I, Beetz N, Sennewald R, et al. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgrad Med 2020; 132(4): 337-45.
[http://dx.doi.org/10.1080/00325481.2020.1750228] [PMID: 32366156]
[33]
Trijardy XR: FDA-approved drugs. US food and drug administration (FDA)

Rights & Permissions Print Cite
Article Metrics
32
1
© 2024 Bentham Science Publishers | Privacy Policy